Mukul Bhattarai, MD

Mukul Bhattarai, MD

Cardiologist
Cardiology
Accepting new patients
Call for an appointment
217-545-8000
or
Request appointment
Languages:
English, Hindi, Nepali, Spanish

    About me

    Gender

    Male

    Additional languages spoken

    Hindi,
    Nepali,
    Spanish

    Education & training

    Positions
    Assistant Professor
    Board Certifications
    General Cardiology
    Internal Medicine
    Nuclear Cardiology
    American Board of Echocardiography
    Board of Cardiovascular Computed Tomography
    Medical School
    Universal College of Medical Sciences, Bhairahawa, Nepal
    Undergraduate Degree
    Tri-Chandra Multiple Campus, Kathmandu, Nepal
    Residency
    Geisinger Medical Center, Danville, Pennsylvania
    Fellowship
    Cardiovascular Disease Fellowship, SIU School of Medicine, Springfield, Illinois

    Specialties

    Conditions

    Patients in waiting room

    Appointments

    SIU Medicine strongly encourages all patients to verify coverage, benefits and which providers are considered in-network with their health plan. SIU Medicine has more than 300 health care providers ready to serve you and your family. SIU Medicine accepts a wide variety of governmental and non-governmental health plans to serve our community. 

    Clinical locations

    Locations

    SIU Medicine Cardiothoracic Surgery | Baylis Medical Building

    747 N. Rutledge Street Springfield, IL 62702 4th Floor
    Get Directions
    Mon - Fri: 8:00 am-4:30 pm
    217-545-8000
    Locations

    SIU Medicine Vascular Surgery | Baylis Medical Building

    747 N. Rutledge Street Springfield, IL 62702 4th Floor
    Get Directions
    Mon - Fri: 8:00 am-4:30 pm
    217-545-8000
    Locations

    SIU Medicine Family Medicine Outpatient Clinic | Springfield

    520 N. 4th St. Springfield, IL 62702
    Get Directions
    Mon - Fri: 8:00 am-5:00 pm
    217-545-8000

    Clinical trials

    Trial
    Cardiology

    Dal-GenE-2: A phase 3, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS)

    Active recruiting
    The primary objective of this trial is to evaluate the potential of dalcetrapib to reduce the occurrence of fatal and non-fatal myocardial infarction in subjects with a documented recent ACS and the AA genotype at variant rs1967309 in the ADCY9 gene.
    Contact: Madison Hollinshead 217-545-9738
    Trial
    Cardiology

    Dal-GenE-2: A phase 3, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS)

    Active recruiting
    The primary objective of this trial is to evaluate the potential of dalcetrapib to reduce the occurrence of fatal and non-fatal myocardial infarction in subjects with a documented recent ACS and the AA genotype at variant rs1967309 in the ADCY9 gene.
    Contact: Madison Hollinshead 217-545-9738